How severe is CVE-2018-14787?

CVE-2018-14787 has a CVSS 3.x base score of 7.8, rated high severity. It is exploitable over local access with low attack complexity, requires low privileges and no user interaction. Impact on confidentiality is high, integrity high, and availability high.

Is CVE-2018-14787 being actively exploited?

It is not currently listed in CISA's KEV catalog. Its EPSS exploit-prediction score is 0% (31st percentile), an estimate of the probability of exploitation in the next 30 days.

What products are affected by CVE-2018-14787?

CVE-2018-14787 primarily affects Philips Intellispace Cardiovascular. In total, 2 product configurations (CPEs) are listed as vulnerable; see the affected-products list for the exact versions.

How do I fix CVE-2018-14787?

Review the linked vendor and NVD advisories for patched versions and mitigations, then upgrade or apply the recommended workaround. Given its high severity, prioritise patching exposed systems.

When was CVE-2018-14787 published?

CVE-2018-14787 was published on 2018-08-22 and last updated on 2026-06-17.

CVE-2018-14787

CVE-2018-14787 is a high-severity vulnerability in Philips Intellispace Cardiovascular with a CVSS 3.x base score of 7.8. It is not currently listed as actively exploited by CISA, and its EPSS exploit-prediction score is low. The underlying weakness is classified as CWE-269.

Key facts

Severity: High (CVSS 3.x base score 7.8)
CVSS v2: 4.6
EPSS exploit prediction: 0% (31st percentile)
Actively exploited: Not listed in CISA KEV
Weakness: CWE-269
Affected product: Philips Intellispace Cardiovascular
Published: 2018-08-22
Last modified: 2026-06-17

Description

In Philips' IntelliSpace Cardiovascular (ISCV) products (ISCV Version 2.x or prior and Xcelera Version 4.1 or prior), an attacker with escalated privileges could access folders which contain executables where authenticated users have write permissions, and could then execute arbitrary code with local administrative permissions.

Frequently asked questions

What is CVE-2018-14787?: In Philips' IntelliSpace Cardiovascular (ISCV) products (ISCV Version 2.x or prior and Xcelera Version 4.1 or prior), an attacker with escalated privileges could access folders which contain executables where authenticated users have write permissions, and could then execute arbitrary code with local administrative permissions.
How severe is CVE-2018-14787?: CVE-2018-14787 has a CVSS 3.x base score of 7.8, rated high severity. It is exploitable over local access with low attack complexity, requires low privileges and no user interaction. Impact on confidentiality is high, integrity high, and availability high.
Is CVE-2018-14787 being actively exploited?: It is not currently listed in CISA's KEV catalog. Its EPSS exploit-prediction score is 0% (31st percentile), an estimate of the probability of exploitation in the next 30 days.
What products are affected by CVE-2018-14787?: CVE-2018-14787 primarily affects Philips Intellispace Cardiovascular. In total, 2 product configurations (CPEs) are listed as vulnerable; see the affected-products list for the exact versions.
How do I fix CVE-2018-14787?: Review the linked vendor and NVD advisories for patched versions and mitigations, then upgrade or apply the recommended workaround. Given its high severity, prioritise patching exposed systems.
When was CVE-2018-14787 published?: CVE-2018-14787 was published on 2018-08-22 and last updated on 2026-06-17.

References

Affected products (2)

cpe:2.3:a:philips:intellispace_cardiovascular:*:*:*:*:*:*:*:*
cpe:2.3:a:philips:xcelera:*:*:*:*:*:*:*:*

More vulnerabilities in Philips Intellispace Cardiovascular

CVE-2017-14111 — High (CVSS 7.2): The workstation logging function in Philips IntelliSpace Cardiovascular (ISCV) 2.3.0 and earlier and Xcelera R4.1L1 and…
CVE-2018-14789 — Medium (CVSS 6.7): In Philips' IntelliSpace Cardiovascular (ISCV) products (ISCV Version 3.1 or prior and Xcelera Version 4.1 or prior),…
CVE-2018-5438 — Medium (CVSS 6.3): Philips ISCV application prior to version 2.3.0 has an insufficient session expiration vulnerability where an attacker…

All CVEs affecting Philips Intellispace Cardiovascular →

Other CWE-269 (Improper Privilege Management) vulnerabilities

CVE-2026-31852 — Critical (CVSS 10.0): Jellyfin is an open-source media system. The code-quality.yml GitHub Actions workflow in jellyfin/jellyfin-ios is…
CVE-2025-20282 — Critical (CVSS 10.0): A vulnerability in an internal API of Cisco ISE and Cisco ISE-PIC could allow an unauthenticated, remote attacker to…
CVE-2025-0505 — Critical (CVSS 10.0): On Arista CloudVision systems (virtual or physical on-premise deployments), Zero Touch Provisioning can be used to gain…
CVE-2023-48418 — Critical (CVSS 10.0): In checkDebuggingDisallowed of DeviceVersionFragment.java, there is a possible way to access adb before SUW…
CVE-2023-48419 — Critical (CVSS 10.0): An attacker in the wifi vicinity of a target Google Home can spy on the victim, resulting in Elevation of Privilege
CVE-2023-31273 — Critical (CVSS 10.0): Protection mechanism failure in some Intel DCM software before version 5.2 may allow an unauthenticated user to…

Browse all CWE-269 (Improper Privilege Management) vulnerabilities →